FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML
The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.
Related Articles
Evolving Treatment Paradigms in Lower-Risk MDS: Current Therapeutic Options and Mechanistic Approaches
A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat offer tailored treatment options for anemia in lower-risk ESAs, enabling clinicians…
PD-L1 and HRD Correlation Shows Prognostic Value in Ovarian Cancer
New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.
Dr Spigel Covers the AIM-HIGH Trial in Early NSCLC
David Spigel, MD, discusses the pivotal findings from the AIM-HIGH trial in early-stage non-squamous NSCLC.
FDA Draft Guidance Illuminates MDS Drug Development Pathways
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer
Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.
Dr Turk on Persistent Unmet Needs in Colorectal Cancer Treatment
Anita Turk, MD, discusses the unmet needs that still exist in the realm of colorectal cancer treatment and management.
Monotherapy Shows Promise in ET and MF as Trials Advance Globally
Early data show promising platelet and molecular responses with monoclonal antibody monotherapy in ET and MF, with trials ongoing in the US and abroad.
Venetoclax Consolidation After BTKi Shows Promise in CLL
A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.
Key Takeaways of Trials in Metastatic CRC Explored
Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.
Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.